“Half-life-extended Monoclonal Antibody APG777 for Atopic Dermatitis: Design of the Phase 2 APEX Study” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s456. doi:10.25251/skin.8.supp.456.